DMKPQ (DMK Pharmaceuticals) YoY EBITDA Growth: 87.16% (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals YoY EBITDA Growth?

DMK Pharmaceuticals DMKPQ -99.00% 16 YoY EBITDA Growth is 87.16% as of Sep. 2023. GuruFocus rates DMKPQ with a GF Score™ of 16/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. DMK Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was 87.16%.

DMK Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2023 was $-0.23.

DMK Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for DMK Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals YoY EBITDA Growth Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.08 50.39 5.81 50.81 25.99

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.80 61.83 18.35 28.18 87.16
DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

DMK Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-11.011--14.878)/ | -14.878 |
=25.99 %

DMK Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (Q: Sep. 2023 )
=(EBITDA per Share (Q: Sep. 2023 )-EBITDA per Share (Q: Sep. 2022 )) / | EBITDA per Share (Q: Sep. 2022 )) |
=(-0.232--1.807)/ | -1.807 |
=87.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 87.16% mean?
DMK Pharmaceuticals (DMKPQ) has a YoY EBITDA Growth of 87.16% as of Sep. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' YoY EBITDA Growth too high?
DMK Pharmaceuticals' current YoY EBITDA Growth is 87.16%. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' YoY EBITDA Growth compare to CNNC and THCT?
DMK Pharmaceuticals' YoY EBITDA Growth of 87.16% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for DMK Pharmaceuticals and its competitors. DMK Pharmaceuticals's current YoY EBITDA Growth is 87.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current YoY EBITDA Growth of 87.16%. The current YoY EBITDA Growth is 87.16%. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current YoY EBITDA Growth is 87.16% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price